| Targeted therapies in diabetic nephropathy: an update. | |
| | |
MedLine Citation:
|
PMID: 22058027 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Diabetic nephropathy is the most common cause of end-stage renal disease worldwide. Various pathways in addition to the renin-angiotensinogen system have been implicated in the pathogenesis of diabetic nephropathy. Strategies to interrupt these pathophysiological pathways are a key to the development of new targeted therapies to prevent progression of diabetic nephropathy and are on the horizon. The various pharmacological drugs tried include aliskiren, a direct renin inhibitor blocking the first step in the renin pathway, and pentoxifylline and mammalian target of rapamycin inhibitors, which have antiinflammatory properties and have shown some promising results in management of diabetic nephropathy. Others include endothelin antagonists and vitamin D analogs which have been shown to decrease urinary albumin excretion. Inhibitors of advanced glycation and oxidative stress and plasminogen activator inhibitor-1 have proved useful in animal models of diabetic nephropathy. Others include ruboxistaurin, which blocks protein kinase C overexpression. Such targeted therapies would halt and might even reverse progression of diabetic nephropathy. |
| | |
Authors:
|
Ankur Gupta; Preeti Gupta; Mohan Biyani |
Related Documents
:
|
21680987 - A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose... 22104467 - The pharmacologic basis for clinical differences among glp-1 receptor agonists and dpp-... 3885867 - Residual insulin secretion in insulin dependent diabetes mellitus. 3290917 - Incidence, prevalence and risk factors for non-insulin-dependent diabetes mellitus. 12785127 - The need for reappraisal of type 2 diabetes mellitus management. 14534077 - Insulin/igf-i-signaling pathway: an evolutionarily conserved mechanism of longevity fro... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of nephrology Volume: 24 ISSN: 1724-6059 ISO Abbreviation: J. Nephrol. Publication Date: 2011 Nov-Dec |
Date Detail:
|
Created Date: 2011-11-07 Completed Date: 2012-04-18 Revised Date: 2012-04-27 |
Medline Journal Info:
|
Nlm Unique ID: 9012268 Medline TA: J Nephrol Country: Italy |
Other Details:
|
Languages: eng Pagination: 686-95 Citation Subset: IM |
Affiliation:
|
Nephrology Division, University of Ottawa, Ottawa, Ontario, Canada. parthankur@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetic Nephropathies
/
drug therapy*,
physiopathology Disease Progression* Humans Molecular Targeted Therapy / trends* Pentoxifylline / pharmacology, therapeutic use Receptors, Endothelin / antagonists & inhibitors Renin / antagonists & inhibitors Renin-Angiotensin System / drug effects, physiology Signal Transduction / drug effects, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Receptors, Endothelin; 6493-05-6/Pentoxifylline; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Should we shift toward higher blood pressure targets in patients with chronic kidney disease.
Next Document: Simultaneous multicystic kidney and Anderson-Fabry disease: 2 separate entities or same side of the ...